Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
Open Access
- 1 November 1994
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 57 (11) , 1355-1359
- https://doi.org/10.1136/jnnp.57.11.1355
Abstract
In a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. An electrogoniometer was used to assess muscle tone at knee extensors, applying Wartenberg's pendulum test. Blood samples, a clinical assessment of muscle tone by the Ashworth scale, and muscle strength by the British Medical Research Council scale were obtained concomitantly. Confirmatory analysis using the change in the relaxation index (R2 value) 1.5 hours after each treatment, showed a statistically significant (p = 0.0123) linear dose-response relation between single doses and antispastic action of tizanidine. Further statistical analysis showed a strong within patient linear correlation between plasma concentrations and antispastic action at 4 and 8 mg doses (p = 0.014 and 0.004 respectively), but only weak between patient correlations. The analysis of the dose-plasma concentration relation showed results consistent with linear pharmacokinetics. The comparison of changes in the R2 ratio with concomitant Ashworth scores showed a significant correlation between the two. It is concluded that there are linear correlations between single doses, plasma concentrations, and antispastic action of tizanidine. Because of the strong within patient but weak between patient correlation between plasma concentrations and antispastic action of tizanidine the effective doses should be determined individually.Keywords
This publication has 15 references indexed in Scilit:
- Does the Wartenberg pendulum test differentiate quantitatively between spasticity and rigidity? A study in elderly stroke and Parkinsonian patients.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patientsActa Neurologica Scandinavica, 1988
- Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosisCurrent Medical Research and Opinion, 1988
- Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at α2-adrenoceptorsNeuroscience Letters, 1984
- Pendulum testing of spasticityJournal of Biomedical Engineering, 1984
- Spinal interneurone depression by DS103–282British Journal of Pharmacology, 1983
- SELECTIVE DEPRESSION OF SYNAPTIC TRANSMISSION OF SPINAL NEURONES IN THE CAT BY A NEW CENTRALLY ACTING MUSCLE RELAXANT, 5‐CHLORO‐4‐(2‐IMIDAZOLIN‐2‐YL‐AMINO)‐2, 1, 3‐BENZOTHIODAZOLE (DS103–282)British Journal of Pharmacology, 1982
- Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresisJournal of the Neurological Sciences, 1982
- Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.Journal of Neurology, Neurosurgery & Psychiatry, 1980
- Pendulousness of the Legs as a Diagnostic TestNeurology, 1951